Ketamine for Depression and Suicide Risk (Ketamine)
Acute and Maintenance Intravenous Ketamine for Treatment Resistant Major Depression With Suicidal Ideation/Attempt
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Current psychiatric hospital inpatient at Mayo Clinic at time of initiation of treatment.
- Ability to provide informed consent
- Male/Female
- Age 18-65 yrs.
- Major Depressive Disorder or Bipolar Disorder I or Bipolar Disorder II with Patient Health Questionnaire-9 (PHQ 9) score ≥15 at hospital assessment
- Treatment resistant depression (TRD) as defined by at least two previous antidepressant or mood stabilizing treatments for depression in adequate dose for 8 weeks
- Patient reported overall suicide risk score ≥3 on the Suicide Status Form (SSF II-R) or score of ≥1on Item 9 of PHQ-9 (all at admission assessment)
- Ability to pass comprehension assessment test related to effects of ketamine and trial objectives and criteria
- Voluntary admission
Exclusion Criteria:
- Diagnosis of schizophrenia, schizoaffective disorder, or active psychosis
- Index episode of depression greater than 2 years
- Ongoing prescription of ≥4 mg lorazepam equivalents total daily or a.m. dosing of any benzodiazepine at time of assessment
- Currently undergoing electroconvulsive therapy, deep brain stimulation or transcranial magnetic stimulation as acute series or for maintenance
- Any active or unstable medical condition as judged by principal investigator
- Previous use or abuse of methamphetamine, cocaine, stimulants (prescribed and illicit) within past 12 months
- Any current abuse or dependence of alcohol or drugs (except nicotine) and abuse or dependence of drugs and alcohol only in full remission (> 1 month, < 12 months). Patients will be allowed to enroll if their drug and alcohol abuse / dependence is in full (complete, not partial) sustained (> 1 year) remission.
- History of traumatic brain injury
- Developmental delay and intellectual disorder
- Encephalopathy (clinical diagnosis within prior 12 months of delirium)
- Cognitive disorder (mild and major)
- Previous participation in earlier Ketamine trial
- Pregnancy
- Prisoners
- Involuntarily hospitalized
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ketamine infusion
This trial was conducted in 2 phases.
During the acute-phase, i.v.
ketamine was administered thrice-weekly for up to 2 weeks.Those who achieved depressive symptom remission received continuation-phase treatment that consisted of once-weekly i.v.
ketamine infusions for 4 additional weeks.
Remission could occur after any of the 6 acute-phase infusions, at which point the next infusion was the first (of four) continuation-phase infusions.
Individuals who remitted during acute-phase and completed continuation-phase treatment had 4 additional weekly post-continuation follow-up visits.
|
0.3 mg/kg/hr of ketamine infused for 100 minutes
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MADRS Total Score at Baseline and Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The Montgomery Asberg Depression Scale (MADRS) is a 10-item observer rating scale assessing symptoms of depression.
The score ranges from 0 (no depression) to 60 (very depressed).
For this study a score of less than or equal to 9 was considered clinical remission of depression.
|
baseline, last acute phase observation (approximately 2 weeks)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MADRS Total Score, Percent Change From Baseline at Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The Montgomery Asberg Depression Scale (MADRS) is a 10-item observer rating scale assessing symptoms of depression.
The score ranges from 0 (no depression) to 60 (very depressed).
For this study a score of less than or equal to 9 was considered clinical remission of depression.
|
baseline, last acute phase observation (approximately 2 weeks)
|
|
MADRS Factor 1 Score at Baseline and Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms.
MADRS Factor 1 (Sadness) consisted of MADRS items 1 (Apparent Sadness) and 2 (Reported Sadness).
The MADRS Factor 1 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12.
|
baseline, last acute phase observation (approximately 2 weeks)
|
|
MADRS Factor 1 Score, Percent Change From Baseline at Last Acute Phase Observation
Time Frame: baseline, last acute phase observation
|
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms.
MADRS Factor 1 (Sadness) consisted of MADRS items 1 (Apparent Sadness) and 2 (Reported Sadness).
The MADRS Factor 1 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12.
|
baseline, last acute phase observation
|
|
MADRS Factor 2 Score at Baseline and Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms.
MADRS Factor 2 (Negative Thoughts) consisted of MADRS items 9 (Pessimistic Thoughts) and 10 (Suicidal Thoughts).
The MADRS Factor 2 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12.
|
baseline, last acute phase observation (approximately 2 weeks)
|
|
MADRS Factor 2 Score, Percentage Change From Baseline at Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms.
MADRS Factor 2 (negative thoughts) consisted of MADRS items 9 (Pessimistic Thoughts) and 10 (Suicidal Thoughts).
The MADRS Factor 2 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12.
|
baseline, last acute phase observation (approximately 2 weeks)
|
|
MADRS Factor 3 Score at Baseline and Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms.
MADRS Factor 3 (Detachment) consisted of MADRS items 6 - 8 (Concentration Difficulties, Lassitude, and Inability to Feel).
The MADRS Factor 3 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18.
|
baseline, last acute phase observation (approximately 2 weeks)
|
|
MADRS Factor 3 Score, Percentage Change From Baseline at Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms.
MADRS Factor 3 (detachment) consisted of MADRS items 6 - 8 (Concentration Difficulties, Lassitude, and Inability to Feel).
The MADRS Factor 3 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18.
|
baseline, last acute phase observation (approximately 2 weeks)
|
|
MADRS Factor 4 Score at Baseline and Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms.
MADRS Factor 4 (Neurovegetative Symptoms) consisted of MADRS items 3-5 (Inner Tension, Reduced Sleep, and Reduced Appetite).
The MADRS Factor 4 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18.
|
baseline, last acute phase observation (approximately 2 weeks)
|
|
MADRS Factor 4 Score, Percentage Change From Baseline at Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms.
MADRS Factor 4 (neurovegetative symptoms) consisted of MADRS items 3-5 (Inner Tension, Reduced Sleep, and Reduced Appetite).
The MADRS Factor 4 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18.
|
baseline, last acute phase observation (approximately 2 weeks)
|
|
MADRS Suicide Thoughts (Item 10) Score at Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms.
Item 10 scores can range from 0 to 6 (with 0 indicating enjoying life, and 6 indicating explicit plans for suicide.)
|
baseline, last acute phase observation (approximately 2 weeks)
|
|
MADRS Suicide (Item 10) Score, Percentage Change From Baseline at Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms.
Item 10 scores can range from 0 to 6 (with 0 indicating enjoying life, and 6 indicating explicit plans for suicide.)
|
baseline, last acute phase observation (approximately 2 weeks)
|
|
Clinical Global Impression-severity Subscale (CGI-S) at Baseline and Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The Clinical Global Impression Severity Subscale is an observer rated scale that measures illness severity.
It has a range of responses from 1 (normal) through to 7 (among the most extremely ill patients).
|
baseline, last acute phase observation (approximately 2 weeks)
|
|
CGI-S Score, Percentage Change From Baseline at Last Acute Phase Observation
Time Frame: baseline, last acute phase observation (approximately 2 weeks)
|
The Clinical Global Impression Severity Subscale is an observer rated scale that measures illness severity.
It has a range of responses from 1 (normal) through to 7 (among the most extremely ill patients).
|
baseline, last acute phase observation (approximately 2 weeks)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: William V Bobo, MD, Consultant - Psychiatry
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Self-Injurious Behavior
- Depression
- Depressive Disorder
- Suicide
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
Other Study ID Numbers
- 13-005152
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.